afasevikumab (NI 1401) / Roche, LightChain Bioscience - LARVOL DELTA

Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies. (PubMed, Sci Rep) - "We have identified three therapeutic antibodies, Tremelimumab, Ipilimumab and Afasevikumab. Further, these candidate antibodies can also be explored in diagnostic test kits for SARS-CoV-2 infection. We opine that this in silico workflow to screen and analyze antibodies for repurposing would have widespread applications."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IL17A